The clinical implications of our findings are quite significant, as there are currently no biomarkers available to predict which patients may be susceptible to CIC.
← all excerpts
Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents.
1
—
—